4D Molecular Therapeutics... (FDMT)
4D Molecular Therapeutics Statistics
Share Statistics
4D Molecular Therapeutics has 46.3M shares outstanding. The number of shares has increased by -10.45% in one year.
Shares Outstanding | 46.3M |
Shares Change (YoY) | -10.45% |
Shares Change (QoQ) | 0.16% |
Owned by Institutions (%) | 84.35% |
Shares Floating | 39.64M |
Failed to Deliver (FTD) Shares | 2.48K |
FTD / Avg. Volume | 0.3% |
Short Selling Information
The latest short interest is 7.67M, so 16.6% of the outstanding shares have been sold short.
Short Interest | 7.67M |
Short % of Shares Out | 16.6% |
Short % of Float | 20.12% |
Short Ratio (days to cover) | 6.9 |
Valuation Ratios
The PE ratio is -1.87 and the forward PE ratio is -1.29. 4D Molecular Therapeutics's PEG ratio is -0.12.
PE Ratio | -1.87 |
Forward PE | -1.29 |
PS Ratio | 8120.72 |
Forward PS | 1.2 |
PB Ratio | 0.59 |
P/FCF Ratio | -2.23 |
PEG Ratio | -0.12 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for 4D Molecular Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.92, with a Debt / Equity ratio of 0.05.
Current Ratio | 14.92 |
Quick Ratio | 14.92 |
Debt / Equity | 0.05 |
Debt / EBITDA | -0.13 |
Debt / FCF | -0.18 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $163 |
Profits Per Employee | $-708.67K |
Employee Count | 227 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -88.29% in the last 52 weeks. The beta is 2.82, so 4D Molecular Therapeutics's price volatility has been higher than the market average.
Beta | 2.82 |
52-Week Price Change | -88.29% |
50-Day Moving Average | 4.49 |
200-Day Moving Average | 10.39 |
Relative Strength Index (RSI) | 35.19 |
Average Volume (20 Days) | 816.86K |
Income Statement
In the last 12 months, 4D Molecular Therapeutics had revenue of 37K and earned -160.87M in profits. Earnings per share was -2.98.
Revenue | 37K |
Gross Profit | 37K |
Operating Income | -187.84M |
Net Income | -160.87M |
EBITDA | -187.84M |
EBIT | -187.84M |
Earnings Per Share (EPS) | -2.98 |
Balance Sheet
The company has 149.34M in cash and 24.61M in debt, giving a net cash position of 124.73M.
Cash & Cash Equivalents | 149.34M |
Total Debt | 24.61M |
Net Cash | 124.73M |
Retained Earnings | -576.2M |
Total Assets | 560.38M |
Working Capital | 405.78M |
Cash Flow
In the last 12 months, operating cash flow was -134.59M and capital expenditures 0, giving a free cash flow of -134.59M.
Operating Cash Flow | -134.59M |
Capital Expenditures | 0 |
Free Cash Flow | -134.59M |
FCF Per Share | -2.49 |
Margins
Gross margin is 100%, with operating and profit margins of -507678.38% and -434778.38%.
Gross Margin | 100% |
Operating Margin | -507678.38% |
Pretax Margin | -434778.38% |
Profit Margin | -434778.38% |
EBITDA Margin | -507678.38% |
EBIT Margin | -507678.38% |
FCF Margin | -363743.24% |
Dividends & Yields
FDMT does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for FDMT is $36, which is 1000.9% higher than the current price. The consensus rating is "Buy".
Price Target | $36 |
Price Target Difference | 1000.9% |
Analyst Consensus | Buy |
Analyst Count | 9 |
Scores
Altman Z-Score | -0.01 |
Piotroski F-Score | 2 |